pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Zelboraf
drug · small molecule
save

vemurafenib

Marketedupdated 3mo ago
by F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 13 investigational indications.

indications

investigational
NSCLC

targets

Serine/threonine-protein kinase B-raf

all catalysts(0)

nothing on the calendar yet

Trials studying vemurafenib

  • phase3A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Studyactive not recruitingn=1,000
  • phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)recruitingn=99
  • phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
  • phase1Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgerycompletedn=47
  • phase2Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Canceractive not recruitingn=24
  • phase2A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)recruitingn=86
  • phase2Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancercompletedn=10
  • phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)recruitingn=720
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 22, 2026
65 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

  • Jun 6, 2032formulationUS 9447089
  • Jul 27, 2030compositionUS 87419203.9y
  • Jun 20, 2029compositionUS 78632882.8y
  • Oct 22, 2026compositionUS 750450965d
  • Aug 2, 2026method-of-use (U-1418)US 8470818
  • Jun 21, 2026compositionUS 8143271

News(1)

  • Labcorp nabs FDA green light for BRAF melanoma diagnostic
    The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.
    fiercebiotech · 8d ago
brand
Zelboraf
trade names
Zelboraf
generic
vemurafenib
MOA
Serine/threonine-protein kinase B-raf inhibitor
indication
Hairy Cell Leukemia
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?